T-Cells

T-Cypher Bio, a biotech company pioneering a novel approach to (T cell receptor) TCR therapeutics has separated from Orbit Discovery to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation of T-Cypher has been financed […]

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing Phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions. These findings are reported in two papers, […]

Researchers are continually looking for processes and technology that give them the edge scientifically or commercially. If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will be beneficial to your work. Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells for improved therapeutics will […]

This webinar looks at T cell exhaustion. This is recognised as a major challenge in the development of immuno-oncology therapies. Used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment. This impairs the T cells’ ability to effectively eradicate cancerous cells. The development of tumour […]